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osting by EAbstract Aim and background: Marrubium vulgare is used in traditional medicine in some coun-
tries such as Mexico in the treatment of diabetes. On the other hand, some studies reported the anti-
oxidant effect of the extract due to its ﬂavonoid content. The current study was designed to
investigate the antidiabetic and antidyslipidemic effects of the methanolic extract of the aerial part
of M. vulgare in streptozotocin-induced diabetic rats.
Materials and methods: The antidiabetic activity of a daily single oral dose of 500 mg/kg/day ofM.
vulgare for 28 days was evaluated by measuring the fasting blood glucose and the peak of blood
glucose level within 120 min of oral glucose tolerance test (OGTT) in diabetic rats. In addition,
the effect of the extract on blood plasma insulin was measured as well as its effect on tissue glycogen
contents in muscles and liver. Moreover, its effect on the oxidant status was evaluated.
Results: M. vulgare signiﬁcantly reduced the blood glucose level starting on the second week. Fur-
thermore, the extract ofM. vulgare showed signiﬁcant increase in plasma insulin and tissue glycogen430919; fax: +966 2 6951696.
m (A.A. Elberry).
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A.A. Elberry et al.38contents. The antidyslipidemic effect was demonstrated by a signiﬁcant reduction in plasma total
cholesterol (TC), triglycerides (TG), and low density lipoprotein-cholesterol (LDL-C), while the
cardio-protective lipid, high density lipoprotein-cholesterol (HDL-C), was increased.
Conclusion: The present data suggest that M. vulgare’s methanolic extract has antihyperglycemic
with antidyslipidemic effect. The protective effect of the extract may be in part due to its antioxidant
activity.
 2011 International Journal of Diabetes Mellitus. Published by Elsevier Ltd. All rights reserved.1. Introduction
Diabetes mellitus is a metabolic disease, characterized by
hyperglycemia together with impaired metabolism of glucose
and other energy-yielding fuels, such as lipids and proteins
[1]. This metabolic disorder is the result of a deﬁciency in insu-
lin secretion or a resistance to insulin action, or both [2]. More
than 220 million people worldwide have diabetes and this
number is likely to more than double by the year of 2030 [3].
Diabetic patients also exhibit oxidative stress, which leads to
lipid peroxidation and tissue damage including retinopathy,
nephropathy, and coronary heart disease [4,5]. Dyslipidemia
or hyperlipidemia is also involved in the development of car-
diovascular complications, which are a major cause of morbid-
ity and mortality [6].
Renewed attention to alternative medicines and natural
therapies has raised researchers’ interest in traditional herbal
medicine. Because of their perceived effectiveness, with mini-
mal side effects in clinical experience and relatively low costs,
herbal drugs are prescribed widely, even when their contents
of the biologically active constituents are unknown [7].
Marrubium vulgare L. (Lamiaceae), commonly known as
‘‘Horehound’’, is a widespread Mediterranean plant used in
folk medicine to cure a variety of diseases, and is widely dis-
tributed in Saudi Arabia. M. vulgare has been widely used in
Mexican traditional medicine for the treatment of DM [8],
and its hypoglycemic effect was demonstrated during the
study of the hypoglycemic effect of some Mexican and Brazil-
ian plants [9,10]. The plant is reported to possess vasorelaxant
[11], antihypertensive [12], analgesic [13], anti-inﬂammatory
[14], and antioxidant properties [15]. The main objective of
our study is to elucidate the effect of M. vulgare on hypergly-
cemia and dyslipidemia in streptozotocin (STZ)-induced dia-
betes in rats.2. Materials and methods
2.1. Chemicals
Streptozotocin (STZ) and a-D-glucose were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Carboxymethylcellulose
sodium (CMC-Na) was purchased from Acros Organics (NJ,
USA), while heparin sodium was purchased from Merck
(Dramstadt, Germany). An insulin kit (Coat-A-Count Insulin)
was purchased from Siemens, Medical Solutions Diagnostics
(Los Angeles, USA), while lipid proﬁle kits were purchased
from Randox Laboratories Ltd. (Antrim, UK). Marrubiin,
the major diterpene in M. vulgare, was isolated according to
the method reported by Kno¨ss et al. [16], and was identiﬁed
by NMR analysis. All other biodiagnostic kits were purchased
from Diagnostic and Research Reagents (Giza, Egypt).2.2. Plant materials and extraction
The aerial part of M. vulgare was collected in December 2009
from Wadi Kama, Al-Taif governorate, Saudi Arabia. It was
dried in the shade and the specimen was deposited in the her-
barium of the College of Pharmacy, King Abdulaziz Univer-
sity, Jeddah, Saudi Arabia (M. vulgare #MV1105). The dried
aerial part (500 g) was homogenized with methanol for
15 min, three times each with 1000 mL using Ultra-turrax
T25 homogenizer (Janke and Kunkel, IKA Labortechnik,
Stauten, Germany) followed by distillation of the solvent
under reduced pressure. The percentage yield was calculated
as 12%, and the dried methanolic extract was kept at 4 C.2.3. Phytochemical analysis
A preliminary phytochemical test to identify the chemical con-
stituents of M. vulgare was carried out according to the meth-
ods of Treas and Evans [17].
2.4. TLC proﬁle of extract
The methanolic extract was analyzed using thin layer chroma-
tography as per ﬁngerprinting using a chromatographic
system as reported by Wagner and Bladt [18]. TLC on Si
gel 60 F254 plates, using CHCL3–MeOH (95:5) as a solvent
system, was used for the identiﬁcation of terpenoid class
compounds, after spraying with Komarowsky reagent. The
extract was also chromatographed on TLC (Si gel 60 F254
plates) using AcOEt–HCOOH–CH3COOH–H2O (100:11:
11:26) as the mobile phase. TLC was observed under UV
254 and 366 nm, before and after spraying with natural prod-
ucts reagent NP/PEG for the detection of ﬂavonoid class
compounds.2.5. Determination of total ﬂavonoids content
Total ﬂavonoid content was measured by means of an alumi-
num chloride colorimetric assay [19] with slight modiﬁcations.
An aliquot (1 ml) of the extract (14.5 mg/10 ml methanol) or
standards solution of quercetin (0.60–1.8 mg/ml) was added
to a 10 ml volumetric ﬂask, containing 4 ml of 50% solution
of methanol. To the ﬂask, 0.3 ml 5% NaNO2 was added. After
5 min, 0.3 ml 10% AlCl3 was added. At the sixth minute, 2 ml
1 M NaOH solution was added and the total volume was made
up to 10 ml with dd H2O. The solution was well mixed, and
absorbance was measured against the prepared reagent, blank
at 510 nm. The total ﬂavonoid content (mg/g) was determined
from the calibration curve, and expressed as mg quercetin
equivalents. All the determinations were carried out in tripli-
cate, and the mean values were calculated.
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Male Wistar rats, weighing 200–250 g, were used in this study,
in accordance with the guidelines of the Biochemical and
Research Ethical Committee at King Abdulaziz University,
Jeddah, Saudi Arabia. Animals were purchased from the ani-
mal house of King Fahd Medical Research Center, King
Abdulaziz University and were housed for one week under
standard conditions (well ventilated, temperature 22 ± 2 C,
relative humidity 50–60% and 12 h day and night cycle). Food
consisted of normal rat chow, and water was provided ad libi-
tum. Care was taken to avoid stressful conditions, and all pro-
cedures were performed between 8 and 10 a.m.
Diabetes was induced through a fresh solution of STZ (in
0.1 M sodium citrate buffer, pH 4.5), injected intraperitoneally
(i.p.) at a dose of 55 mg/kg, as a single dose to overnight fas-
tening rats [20]. Ten days after STZ administration, the rats
with blood glucose concentration of between 20 and
30 mmol/L (360–540 mg/dl) were selected, and divided into
three groups (groups II–IV).
Animals were randomly divided into 4 groups, with 8 ani-
mals in each group. Group I (normal control), received an
equivalent volume of the 0.1 M sodium citrate buffer. Group
II (diabetic control), diabetic rats received a single daily dose
of 1% CMC-Na, as a vehicle for the tested extract, starting
on the 11th day. This group served as a ve control group.
In Group III (the glibenclamide group), diabetic rats received
a single daily dose of glibenclamide in a dose of 5 mg/kg, start-
ing on the 11th day. This group served as a +ve control group.
In Group IV (M. vulgare group), diabetic rats received a plant
extract of M. vulgare in a dose of 500 mg/kg as a single daily
dose, starting on the 11th day. The 500 mg/kg extract dose
used in the treatment was chosen from a preliminary short-
term study in our laboratory. Vehicle, glibenclamide and plant
extract were given orally by gavage as single daily treatments,
for 28 days. Blood samples were collected from tail vein, and
fasting blood glucose of the overnight fasted animals was mea-
sured before and at days 7, 14, 21, and 28 from treatment.
At the end of the experiment, blood samples were with-
drawn, and animals were sacriﬁced through cervical disloca-
tion, under light ether anesthesia, to separate the liver.
Livers were dissected out and retained in liquid nitrogen to
determine the antioxidant status. A 5% tissue homogenate in
ice-cold 0.9% saline was made, and the supernatant was ob-
tained from tissue homogenate by centrifugation (1000g,
4 C, 10 min) for determination of the oxidant status.
2.7. Toxicity study
The rats were givenM. vulgare at increasing doses of 100, 250,
500, and 1000 mg/kg daily, for a period of 3 weeks (six rats
were taken for each dose). The animals were observed contin-
uously during the ﬁrst hour, and then every hour for 6 h, then
after 12 and 24 h, and ﬁnally after every 24 h, up to 3 weeks,
for any physical signs of toxicity such as writhing, gasping, pal-
pitation and respiratory rate, or mortality.
2.8. Evaluation of the effect of M. vulgare extract on plasma
insulin level
At the end of the 28th day, 3 h after the last dose of the sol-
vent, glibenclamide or the extract, blood samples were with-drawn from the orbital sinus of rats, under light ether
anesthesia, into heparinized tubes. Samples were centrifuged
at 3500 rpm for 15 min to separate the plasma. The plasma
samples were separated and kept at 20 C for analysis when
required. Insulin concentrations were determined through a
radioimmunoassay procedure, using insulin kits according to
the manufacturer’s instructions.
2.9. Evaluation of the effect of M. vulgare extract on plasma
glucose and tissue glycogen
Fasting plasma glucose was estimated using the glucose oxi-
dase peroxidase method [21]. Tissue glycogen was estimated
through the method of Morales et al. [22].
2.10. Evaluation of the effect of M. vulgare extract on plasma
lipid proﬁle
Total cholesterol (TC), triglycerides (TG) and HDL-choles-
terol (HDL-C) were determined spectrophotometrically, using
commercial kits. Low density lipoprotein (LDL) was calcu-
lated by using Friedewald formula [23].
2.11. Evaluation of the effect of M. vulgare extract on liver
antioxidant status
Hepatic superoxide dismutase (SOD) activity was determined
according to the method described by Sun and Zigman [24],
while, the activities of hepatic glutathione peroxidase (GPx),
glutathione reductase (GR) and glutathione-S-transferase
(GST) activity were determined according to Mohandas
et al. [25]. Reduced glutathione (GSH) level was measured
according to the chemical method described by Moron et al.
[26], while lipid peroxidation products were determined by
measuring malondialdehyde (MDA) content in tissue homog-
enates, according to the method of Uchiyama and Mihara [27].
2.12. Evaluation of the effect of M. vulgare extract on oral
glucose tolerance test (OGTT)
Twenty four male Wistar rats were divided into other four
groups (six rats in each group) as the ﬁrst protocol. At the
end of the 28th day, 3 h after the last dose of the solvent, gli-
benclamide or the extract, blood samples were withdrawn from
tail vein of overnight fasting rats and blood glucose was deter-
mined, indicating zero time of the test. Glucose solution (50%)
in a dose of 2.5 g/kg [28] was given orally. Blood samples were
withdrawn at 15, 30, 60, 90, and 120 min after glucose loading,
and blood glucose level was determined at these time intervals
using glucometer (Accu-Check Active, Roche). Curves of
blood glucose levels (mg/dl) versus time intervals (min) were
constructed, and the area under the curve (AUC) was calcu-
lated according to the trapezoidal method. The AUCs of the
curves of each group were compared and tested for signiﬁcance
to the control diabetic group, to represent glucose utilization
by the tissues.
2.13. Determination of protein content
The protein content of cardiac tissue homogenates was deter-
mined by the Lowry protein assay using bovine serum albumin
as the standard [29].
40 A.A. Elberry et al.2.14. Statistical analysis
Data are expressed as mean ± standard error (SE) of mean.
Statistical analyses were performed using one-way analysis of
variance (ANOVA). If the overall F-value was found to be sta-
tistically signiﬁcant (P< 0.05), further comparisons among
groups were made according to post hoc Tuckey’s test. All sta-
tistical analyses were performed using GraphPad InStat 3
(GraphPad Software, Inc. La Jolla, CA, USA) software.
3. Results
3.1. Phytochemical analysis
Phytochemical screening of the extracts indicated the presence
of ﬂavonoids, tannins, and sterols and/or terpenoids, and the
absence of alkaloids and saponins.Table 1 Effect of pretreatment with methanolic extract ofM. vulgar
rats.
Groups Blood glucose level (mg/dl)
Before treatment
Day 0 7th day
Normal control 113 ± 3.9 112 ± 2.8
Diabetic control 404 ± 27.2 416 ± 22.8
Diabetic + glibenclamide 421 ± 18.8 466 ± 19.5
Diabetic+M. vulgare 435 ± 29.6 495 ± 3.1
The values are expressed as the mean ± SE of the mean of eight rats in
a Signiﬁcantly reduced from values in day 0 in each corresponding gro
b Signiﬁcantly reduced from control values of diabetic rats in the corre
Table 2 Effects of oral pretreatment with methanolic extract of M
muscle glycogen, and liver glycogen in diabetic rats.
Groups Insulin (lIU/ml) Mu
Normal control 8.48 ± 1.32 11.1
Diabetic control 3.22 ± 0.38a 4.13
Diabetic + glibinclamide 8.47 ± 2.39b 8.41
Diabetic +M. vulgare 6.16 ± 1.26b 9.83
The values are expressed as the mean ± SE of the mean of eight rats in
a Signiﬁcantly different from the values of the normal rats at P< 0.05
b Signiﬁcantly different from the control values of diabetic rats at P<
Table 3 Effects of oral pretreatment with methanolic extract of M
triglycerides (TG), high density lipoprotein (HDL-C) and low densit
Groups TC (mg/dL) TG (m
Normal control 125.71 ± 4.04 87 ± 2
Diabetic control 239.99 ± 21.53a 113.33
Diabetic + glibinclamide 178.28 ± 15.05a,b 121.6 ±
Diabetic +M. vulgare 181.28 ± 17.20a,b 108.80
The values are expressed as the mean ± SE of the mean of eight rats.
a Signiﬁcantly different from the values of the normal control rats at P
b Signiﬁcantly different from the control values of diabetic rats at P<3.2. Determination of total ﬂavonoids content
Assay of total ﬂavonoid content of dried aerial parts of M.
vulgare was determined to be 15.53 mg quercetin equivalent/g
of dry plant material.
3.3. Toxicity study
A toxicity study revealed the non-toxic nature of the extract.
The rats treated with different doses of M. vulgare did not
show any drug-induced physical signs of toxicity during the
whole experimental period, and no deaths were reported.
3.4. Effect of M. vulgare extract on plasma glucose level
Diabetic rats showed a signiﬁcant increase in the levels of plas-
ma glucose when compared to normal rats. Oral administra-e (500 mg/kg/day for 28 days) on blood glucose levels of diabetic
After treatment
14th day 21st day 28th day
110 ± 3.7 100 ± 5.8 121 ± 7.4
443 ± 17.6 480 ± 31.7 498 ± 31.3
453 ± 22.8 386 ± 21.6a,b 345 ± 25.7a,b
405 ± 19.2a,b 355 ± 30.5a,b 337 ± 23.6a,b
each group.
up at P< 0.05.
sponding day at P< 0.05.
. vulgare (500 mg/kg/day for 28 days) on plasma insulin level,
scle glycogen (mg/g tissue) Liver glycogen (mg/g tissue)
2 ± 0.9 54.43 ± 5.4
± 0.2a 22.12 ± 2.3a
± 0.6b 46.13 ± 4.2b
± 0.8b 48.13 ± 5.2b
each group.
.
0.05.
. vulgare (500 mg/kg/day for 28 days) on total cholesterol (TC),
y lipoprotein (LDL-C) of diabetic rats.
g/dL) HDL-C (mg/dL) LDL-C (mg/dL)
.52 29.57 ± 5.47 78.70 ± 4.58
± 11.15a 20.56 ± 3.09a 168.68 ± 8.75a
14.62a 41.84 ± 7.15a,b 112.10 ± 8.02a,b
± 15.09a 42.14 ± 4.81a,b 123.85 ± 16.28a,b
< 0.05.
0.05.
Methanolic extract of Marrubium vulgare ameliorates hyperglycemia and dyslipidemia 41tion of M. vulgare showed a highly signiﬁcant reduction in the
plasma glucose level starting at the 14th day of treatment,
compared to before treatment (day 0) as well as compared to
the control values of diabetic rats in the corresponding days.
This reduction was marked on the 28th day as reaching a
23% reduction, compared to day 0, and a 42% reduction com-
pared to the control values of the diabetic group. On the otherNo
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Figure 1 Effects of pretreatment with methanolic extract of M. vulg
glutathione peroxidase (GPx), glutathione reductase (GR), and gl
Malondialdehyde (MDA) in diabetic rats.hand, glibenclamide treatment of diabetic rats showed a signif-
icant reduction in plasma glucose level on the 21st day of treat-
ment, compared to before treatment and compared also to the
control values of diabetic rats in the corresponding days. The
plasma glucose level was reduced by 18% compared to day 0
and 31% compared to control values of the diabetic group
on the 28th day (Table 1).No
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are (500 mg/kg/day for 28 days) on superoxide dismutase (SOD),
utathione-S-transferase (GST, reduced glutathione (GSH) and
Table 4 Total area under the curve induced after glucose
loading in diabetic rats pretreated with the methanolic extract
of M. vulgare (500 mg/kg/day) for four weeks.
Groups Total AUC (mg/dl min) % Reduction
Normal control 14,479 ± 480.42 –
Diabetic control 70,108 ± 2077.06 0.00
Diabetic + glibenclamide 59,692 ± 1785.26a 15%
Diabetic +M. vulgare 61,350 ± 1512.88a 12%
a Signiﬁcantly different from the control values of diabetic rats at
P< 0.05.
A.A. Elberry et al.423.5. Effect of M. vulgare extract on plasma insulin level, liver
glycogen and muscle glycogen
The plasma insulin level was signiﬁcantly reduced in the
diabetic group. Pretreatment of diabetic rats with M. vulgare
extract or glibenclamide for 4 weeks signiﬁcantly increased
the insulin blood level compared to diabetic control rats
(48%) (Table 2). The muscle and liver glycogen contents de-
creased signiﬁcantly in diabetic rats when compared to normal
rats. M. vulgare extract and glibenclamide treatment signiﬁ-
cantly increased both muscle and liver glycogen, compared to
the diabetic control rats (58% and 54%, respectively) (Table 2).
3.6. Effect of M. vulgare extract on plasma lipid proﬁle
Diabetic rats showed a signiﬁcant increase in the blood levels
of TC, TG, and LDL-C (Table 3). On the other hand, HDL-C
was signiﬁcantly reduced when compared to the values of nor-
mal control rats. Oral administration of glibenclamide signiﬁ-
cantly decreased the blood levels of TC and LDL-C. However,
the level of HDL-C signiﬁcantly increased. Glibinclamide did
not signiﬁcantly change the blood level of TG, when compared
to diabetic control rats. The pretreatment with M. vulgare ex-
tract signiﬁcantly decreased the blood levels of TC (24%) and
LDL-C (27%); however, the blood level of HDL-C was signif-
icantly increased when compared to the values of the diabetic
control rats (27%) (Table 3).
3.7. Effect of M. vulgare extract on hepatic oxidative stress
Streptozotocin administration resulted in a signiﬁcant decrease
in antioxidant enzymatic activity, including GPx, GR, and
GST. Moreover, it caused a signiﬁcant increase in MDA, while
GSH was reduced signiﬁcantly (Fig. 1). M. vulgare extract
exhibited improvements in antioxidant enzymatic activity,
compared to the diabetic control group, and nearly normalized
the level of both GSH and MDA. The activity of SOD was not
signiﬁcantly changed (Fig. 1).
3.8. Effect of M. vulgare extract on OGTT and AUC
The blood levels of glucose in normal control, diabetic control,
and diabetic treated with gibenclamide or M. vulgare extract0 25 50 75 100 125 150
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Figure 2 Effect of methanolic extract of M. vulgare (500 mg/kg/
d) on blood glucose level. The values are expressed as the
mean ± SE of the mean of six rats in each group.groups demonstrated a signiﬁcant change in blood glucose le-
vel after oral loading, with 50% glucose solution (Fig. 2 and
Table 4). The rats in the diabetic group had a signiﬁcant eleva-
tion in blood glucose level throughout the total measurement
period (120 min) with respect to normal control (Fig. 2); more-
over, it did not come back to the initial value (0 min level) even
at the end of the period tested. Pretreatment of diabetic rats
with gibenclamide or M. vulgare extract induced a signiﬁcant
reduction in AUC relative to the diabetic control group by
15% and 12%, respectively (Fig. 2 and Table 4).
4. Discussion
In the present study, diabetes mellitus was induced in rats
through a STZ injection that causes the destruction of b-cells
of islets of Langerhans, as proposed by many authors
[30,31]. This effect was represented in the current study
through the elevation of blood glucose and a decrease of insu-
lin levels in diabetic control rats. The elevated plasma glucose
levels in diabetic rats were lowered through the administration
of M. vulgare, which showed an elevated plasma insulin level
compared to diabetic control rats. The action of M. vulgare
seems to be similar to that of glibenclamide [32].
Earlier phytochemical investigation ofM. vulgare led to the
characterization of several ﬂavonoids [33] that possess hypo-
glycemic, as well as antioxidant properties. Some ﬂavonoids
have hypoglycemic properties because they improve altered
glucose and oxidative metabolisms of the diabetic states [34].
They also exert a stimulatory effect on insulin secretion by
changing Ca++ concentration [35].
Glycogen synthesis in the rat liver and skeletal muscles was
impaired during diabetes [36]; hence glycogen content of skel-
etal muscle and liver was markedly decreased in diabetic rats
[37]. The results of the present study showed an increase in
skeletal muscle and liver glycogen content in diabetic rats after
the oral administration of M. vulgare which may be due to the
stimulation of insulin release from beta cells [38]. Furthermore,
the diabetic control rats showed a signiﬁcant increase in the
AUC of the glucose concentration after oral glucose loading.
This effect may be due to the reduction of glucose tissue utili-
zation and an increased hepatic glucose production, as a result
of decreased insulin production [39]. The administration of
M. vulgare extract produced a signiﬁcant reduction in the
AUC of diabetic control rats. These results revealed that the
M. vulgare extract induced an increase in glucose utilization
and glucose tolerance through the body tissues of diabetic rats.
It is well known that dyslipidemia is associated with uncon-
trolled diabetes mellitus. The plasma levels of TC, LDL-C, and
Methanolic extract of Marrubium vulgare ameliorates hyperglycemia and dyslipidemia 43TG increases, while the HDL levels decline, contributing to
secondary complications of diabetes [40,41]. Acute insulin deﬁ-
ciency initially causes an increase in free fatty acid mobiliza-
tion from adipose tissue. This results in an increased
production of LDL-C particle [42]. In the present study, dia-
betic rats exhibited a signiﬁcant elevation of TC, TG, and
LDL-C, while HDL-C was decreased. M. vulgare administra-
tion resulted in lowering the plasma levels of TC, TG, and
LDL-C with elevation of HDL-C level. It is known that the
administration of insulin to diabetic subjects not only elevates
lipoprotein lipase activity, but also lowers the plasma TG con-
centrations [43]. The presently observed decline in plasma lipid
proﬁles in M. vulgare administered diabetic rats suggests that
the extract’s potential is possibly due to the elevation of insulin
level.
The possible mechanism of the extract may in part be
attributed to its antioxidant activities. Complementing our
ﬁndings, earlier studies have reported that the extract may
have antioxidant activity.M. vulgare leaves have been reported
to be rich in phenolic compounds [44] and these compounds
were previously served as free radical scavengers [45]. Hyper-
glycemia generates reactive oxygen species (ROS), which in
turn cause lipid peroxidation and membrane damage [46].
The current study showed a signiﬁcant reduction in antioxi-
dant enzymes including GPx, GR, and GST in the diabetic rats
with decreased GSH and increased MDA levels indicating oxi-
dative stress. A signiﬁcant improvement in these indictors of
oxidative stress in the liver of M. vulgare treated diabetic rats
is indicative of its ability to reduce body glucose concentration,
and its subsequent oxidation. These effects of M. vulgare on
antioxidants were found to be better than those of glibencla-
mide treated diabetic rats.
In conclusion theM. vulgare has both a hypoglycemic effect
and an antidyslipidemic activity. The possible mechanism of
the antidiabetic action may be through a stimulation of insulin
release from the remnant pancreatic b-cells. Both antidiabetic
and antidyslipedimic effects may in part be due to its antioxi-
dant activity.Conﬂict of interest statement
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